Literature DB >> 10548365

Low endogenous prostaglandin E2 predisposes to relapsing inflammation in experimental rat enterocolitis.

H M Kandil1, R A Argenzio, R B Sartor.   

Abstract

Intramural injection of peptidoglycan-polysaccharide (PG-PS) induces acute enterocolitis that spontaneously relapses in Lewis but not Fischer rats. Interleukin-1 (IL-1) and tumor-necrosis factor-alpha (TNF-alpha) induce prostaglandin E2 (PGE2) secretion, which inhibits secretion of these cytokines by macrophages, suggesting an inhibitory feedback mechanism. We postulate that Lewis rat susceptibility to relapse is due to an imbalance between protective prostaglandins and cytokines. Female Fischer and Lewis rats were injected with PG-PS (37.5 microg/g) or human serum albumin intramurally. Tissue IL-1alpha and PGE2 immunoreactivities and myeloperoxidase (MPO) activity were determined. Relapsing rats had lower PGE2 and PGE2:IL-1alpha ratios than nonrelapsing rats (P < 0.05). In Fischer rats, 2 mg/kg/day indomethacin potentiated cecal MPO and IL-1alpha concentrations above PG-PS alone (P < 0.05). Misoprostol treatment blocked PG-PS-induced IL-1alpha and MPO and inhibited the potentiating effect of indomethacin on MPO and IL-1alpha (P < 0.05). In conclusion, increased endogenous PG may be protective against relapsing inflammation in PG-PS induced enterocolitis, at least partially via inhibition of proinflammatory cytokines. An imbalance between protective prostaglandins and proinflammatory cytokines may be involved in the pathogenesis of chronic relapsing inflammation in genetically susceptible hosts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548365     DOI: 10.1023/a:1026694907238

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

Review 1.  Aspirin, NSAIDS, and colon cancer prevention: mechanisms?

Authors:  R A Gupta; R N DuBois
Journal:  Gastroenterology       Date:  1998-05       Impact factor: 22.682

2.  Regression of rectal adenomas after colectomy and ileorectal anastomosis for familial adenomatous polyposis.

Authors:  R J Nicholls; R G Springall; P Gallagher
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-18

3.  Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats.

Authors:  E M Sternberg; J M Hill; G P Chrousos; T Kamilaris; S J Listwak; P W Gold; R L Wilder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Altered eicosanoid levels in human colon cancer.

Authors:  B Rigas; I S Goldman; L Levine
Journal:  J Lab Clin Med       Date:  1993-11

5.  Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification.

Authors:  K L Isaacs; R B Sartor; S Haskill
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

6.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Authors:  F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

7.  Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1.

Authors:  D Wallach; H Holtmann; H Engelmann; Y Nophar
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

8.  Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam.

Authors:  R F Jacoby; D J Marshall; M A Newton; K Novakovic; K Tutsch; C E Cole; R A Lubet; G J Kelloff; A Verma; A R Moser; W F Dove
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

9.  Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.

Authors:  I I Singer; D W Kawka; S Schloemann; T Tessner; T Riehl; W F Stenson
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

10.  Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation.

Authors:  V Casini-Raggi; L Kam; Y J Chong; C Fiocchi; T T Pizarro; F Cominelli
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

View more
  2 in total

1.  Physiological Concentration of Prostaglandin E2 Exerts Anti-inflammatory Effects by Inhibiting Microglial Production of Superoxide Through a Novel Pathway.

Authors:  Shih-Heng Chen; Yueh-Feng Sung; Esteban A Oyarzabal; Yu-Mei Tan; Jeremy Leonard; Mingri Guo; Shuo Li; Qingshan Wang; Chun-Hsien Chu; Shiou-Lan Chen; Ru-Band Lu; Jau-Shyong Hong
Journal:  Mol Neurobiol       Date:  2018-03-01       Impact factor: 5.590

2.  Decreased total antioxidant capacity in plasma, but not tissue, in experimental colitis.

Authors:  José Wander Breganó; Jane Bandeira Dichi; Décio Sabbatini Barbosa; Mirian Zebian El Kadri; Tiemi Matsuo; Maria Aparecida Rodrigues; Rubens Cecchini; Isaias Dichi
Journal:  Dig Dis Sci       Date:  2008-08-22       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.